IRS2

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.

Key Points: 
  • REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.
  • We achieved significant progress in the advancement of our promising oncology pipeline during the first half of 2021, said Isaac Israel, Chief Executive Officer of Purple Biotech.
  • Initial results from the first dose level cohort showed that NT219 was well-tolerated with minimal serious adverse events.
  • These are factors that we believe could cause our actual results to differ materially from expected results.